Investment Portfolio

OneVentures Innovation Fund (Fund I)

OneVentures Innovation and Growth Fund (Fund II)

Other Investments

OneVentures Innovation Fund I

Hatchtech

www.hatchtech.com.au

Deal lead: Dr Paul Kelly

Hatchtech Pty Ltd. is the developer of a proprietary next generation head lice treatment, DeOvo™, which has successfully completed a Phase III clinical trial. Subject to regulatory approval, market launch is anticipated in 2015.

Awards and Accolades

Vaxxas

www.vaxxas.com

Deal lead: Dr Paul Kelly

Vaxxas is developing  a new medical device for vaccine delivery using a game-changing micro needle technology (Nanopatch™) developed at the University of Queensland. The technology is targeting a multi-billion market and is already receiving strong interest from big pharmaceutical companies for use with their vaccines.

Awards and Accolades

Smart Sparrow

www.smartsparrow.com

Deal lead: Dr Michelle Deaker

Smart Sparrow is an adaptive e-learning company incubated with the University of New South Wales' Faculty of Engineering. OneVentures then led the funding round with Uniseed investing alongside the OneVentures Innovation Fund. Smart Sparrow will utilise the capital injection to enhance platform capability and further pursue market adoption of their state-of-the-art technology.

Awards and Accolades

Paloma Mobile

www.palomamobile.com

Deal lead: Anne-Marie Birkill

Paloma Mobile Pty Ltd is developing and commercialising a cloud-based platform that delivers extremely data-efficient smartphone applications, enabling rich-media services even on the low-end touchscreen smartphones and low-bandwidth networks common in emerging markets, and making such services affordable for consumers on PAYG data plans.

Building IQ

www.buildingiq.com

Deal lead: Dr Michelle Deaker

BuildingIQ is a leading energy management software company whose mission is to redefine the way energy is managed in commercial buildings. BuildingIQ's suite of software offerings are based on unique, patent-pending Predictive Energy Optimization™ technology. The investment was exited in December 2012 to incoming strategic investors.

Incoming Media

www.incoming-media.com

Deal lead: Dr Michelle Deaker

Incoming is an Australian Spin-out from the National ICT Association (NICTA). Incoming enables Digital Media businesses to deliver Personalised HD Mobile Video, reaching a new generation of viewer whose smartphones and tablets are their "1st Screen".

Awards and Accolades

Charmhealth

www.charmhealth.com.au

Deal lead: Dr Paul Kelly and Anne-Marie Birkill

Charmhealth (Charm) is a Brisbane-based company that has developed software solutions to mitigate risk, improve care outcomes and reduce the costs of care for patients with cancer. Charm's Oncology Information Management System (OIMS) is a stand alone software solution that integrates with other applications in the public and private healthcare systems to support clinicians with patient care - including prescriptions, radiology, chemotherapy, and transplant support within a single patient-centric electronic medical record that can be shared across facilities.

Peak3

www.peak3.com.au

Deal lead: Anne-Marie Birkill

Peak3 is a Queensland-based company focused on the reduction and monitoring of emissions in mines. OneVentures will work with Peak3 to finalise product development, complete first commercial trials and develop and exploit markets, initially in the mining industry.

Beasy (formerly TheBestDay)

www.thebestday.com

Deal lead: Anne-Marie Birkill

Beasy (formerly TheBestDay) Pty Ltd is developing and taking to market a social planning tool for the web and phone that makes it easy for a group to agree on details of an activity, including time and place.

OneVentures Innovation and Growth Fund (Fund II)

Find-Me Technologies Pty Ltd

www.carerswatch.com.au

Deal lead: Anne-Marie Birkill

Find-Me Technologies is the creator of the Carers Watch, a product developed to assist in the care of patients with dementia. One of the problems associated with dementia is patients' tendency to wander. It is estimated that 60% of the world's 48 million dementia sufferers wander. A person with Alzheimer's may not remember his or her name or address, and can become disoriented, even in familiar places. Wandering among people with dementia is dangerous and can result in injury, illness or death. The Carers Watch is a wrist worn device designed to discreetly communicate with, locate and monitor patients that wander.

Clinical Genomics Technologies Pty Ltd

www.clinicalgenomics.com

Deal lead: Dr Paul Kelly

Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer diagnosis and monitoring. With a broad intellectual property portfolio including more than 20 issued and pending patents, Clinical Genomics has developed and validated a sensitive and specific blood test for colorectal cancer recurrence monitoring that will be launched in the U.S. in 2016. This 2-gene test, which is based on methylated DNA from two genes, BCAT1 and IKZF1, is currently known by its project name GEMINI.

Clinical Genomics, via its wholly-owned subsidiary Enterix Inc., currently offers the user-friendly, patient-preferred colorectal cancer screening InSure® FIT™ assay, a fecal immunochemical test that detects blood in the stool. InSure FIT is also marketed as a lab-based test in Australia as ColoVantage Home.

With offices and laboratories in Bridgewater and Edison, New Jersey and Sydney, Australia, Clinical Genomics operates as an FDA-registered and TGA-certified manufacturer and a NATA-accredited laboratory.

Vaxxas

www.vaxxas.com

Deal lead: Dr Paul Kelly

Vaxxas is developing  a new medical device for vaccine delivery using a game-changing micro needle technology (Nanopatch™) developed at the University of Queensland. The technology is targeting a multi-billion market and is already receiving strong interest from big pharmaceutical companies for use with their vaccines.

Awards and Accolades

Employment Hero

employmenthero.com

Deal lead: Dr Michelle Deaker

Employment Hero aims to become the employment platform of choice for employers and employees in Australia and beyond, by providing free, easy-to-use HR software that employers love to use, and access to far amazing benefits for employees.

8i

8i.com

Deal lead: Dr Michelle Deaker

8i is a virtual reality software company focusing on volumetric human capture. The company was founded in Wellington, New Zealand and has since expanded to Los Angeles and San Francisco.

Other Investments

AgaMatrix

www.agamatrix.com

AgaMatrix develops and manufactures a line of diabetes products designed to improve the quality of diabetes care. The company's products feature WaveSense, a new technology that personalises each test to provide world class accuracy. It detects and corrects for many errors caused by differences in blood samples and environmental conditions.